Influence of AGT, TGFB1, ESR1, and VDR gene variants on development and course of idiopathic interstitial pneumonias and pulmonary sarcoidosis

The aim of the study was to estimate the contribution of angiotensinogen (AGT), transforming growth factor beta-1 (TGFB1), estrogen receptor alpha (ESR1), and vitamin D receptor (VDR) gene variants to IIP and PS development and course in residents of Russian Federation. Methods. This case-control study involved 104 IIP patients, 111 PS patients, and 113 controls. Seven single nucleotide polymorphisms were investigated using polymerase chain reaction followed by restriction analysis, namely rs5051 in AGT gene; rs1800469, rs1800470, and rs1800471 in TGFB1 gene; rs2234693 and rs9340799 in ESR1 gene; rs731236 in VDR gene. Results. We revealed associations of TGFB1 (rs1800469) and ESR1 (rs9340799) gene variants with IIP clinical outcomes, as well as AGT (rs5051) and VDR (rs731236) gene variants with PS stage. Unfavorable IIP outcomes, i.e. IIP progression or death, were associated with variants rs1800469 СС in TGFB1 gene (р = 0.021; odds ratio (OR) = 2.83; 95%CI: 1.16–6.94) and rs9340799 X (G) in ESR1 gene (р = 0.012; OR = 3.18; 95%CI: 1.27–8.00), as well as with their combination (р = 0.003; OR = 3.88; 95%CI: 1.55–9.71). PS stages II–IV were associated with variants rs5051 А in AGT gene (р = 0.010; OR = 3.22; 95%CI: 1.30–7.98) and rs731236 t (C) in VDR gene (р = 0.046; OR = 2.45; 95%CI: 1.00–6.02), as well as with their combination (р = 0.041; OR = 3.31; 95%CI: 1.14–9.60). Conclusion. Results of the study contribute to understanding genetic factors that influence IIP and PS courses.

interstitial lung diseases, idiopathic interstitial pneumonias, sarcoidosis, genes, single nucleotide polymorphism

1. Il'kovich M.M., ed. Interstitial and orphan lung diseases. Moscow: GEOTAR-Media; 2016 (in Russian).

2. Kreuter M., Herth F.J., Wacker M. et al. Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry –The EXCITING-ILD Registry. Biomed. Res. Int. 2015; 2015: 123876. DOI: 10.1155/2015/123876.

3. Bajwa A., Osmanzada D., Osmanzada S. et al. Epidemiology of uveitis in the mid-Atlantic United States. Clin. Ophthalmol. 2015; (9): 889–901. DOI: 10.2147/OPTH.S80972.

4. Mirsaeidi M., Machado R.F., Schraufnagel D. et al. Racial difference in sarcoidosis mortality in the United States. Chest. 2015; 147 (2): 438–449. DOI: 10.1378/chest.14-1120.

5. Il'kovich M.M., Novikova L.N., Speranskaya A.A. Idiopathic pulmonary fibrosis: current issues. Consilium Medicum. 2009; (11): 24–29 (in Russian).

6. Chuchalin A.G., Vizel' A.A, Il'kovich M.M. et al. Diagnosis and treatment of sarcoidosis: summary of Federal Consensus Guidelines. Part 1. Classification, etiology, pathogenesis, and clinical course. Vestnik sovremennoy klinicheskoy meditsiny. 2014; 7 (4): 62–70 (in Russian).

7. Inoue I., Nakajima T., Williams C.S. et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J. Clin. Invest. 1997; 99 (7): 1786–1797. DOI: 10.1172/JCI119343.

8. Shu X.O., Gao Y.T., Cai Q. et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res. 2004; 64 (3): 836–839.

9. van Meurs J.B., Schuit S.C., Weel A.E. et al. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum. Mol. Genet. 2003; 12 (14): 1745–1754.

10. Horst-Sikorska W., Kalak R., Wawrzyniak A. et al. Association analysis of the polymorphisms of the VDR gene with bone mineral density and the occurrence of fractures. J. Bone Miner. Metab. 2007; 25 (5): 310–319. DOI: 10.1007/s00774-007-0769-5.

11. Hofmann S., Fischer A., Nothnagel M. et al. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. Eur. Respir. J. 2013; 41 (4): 888–900. DOI:10.1183/09031936.00033812.

12. Fingerlin T.E., Zhang W., Yang I.V. et al. Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genet. 2016; 17 (1): 74. DOI: 10.1186/s12863-016-0377-2.

13. Fischer A., Grunewald J., Spagnolo P. et al. Genetics of sarcoidosis. Semin. Respir. Crit. Care Med. 2014; 35 (3): 296–306. DOI: 10.1055/s-0034-1376860.

14. Zhou W., Wang Y. Candidate genes of idiopathic pulmonary fibrosis: current evidence and research. Appl. Clin. Genet. 2016; (9): 5–13. DOI: 10.2147/TACG.S61999.

15. Molina-Molina M., Xaubet A., Li X. et al. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 2008; 32 (4): 1004–1008. DOI: 10.1183/09031936.00015808.

16. Arja C., Ravuri R.R., Pulamaghatta V.N. et al. Genetic determinants of chronic obstructive pulmonary disease in South Indian male smokers. PLoS One. 2014; 9 (2): e89957. DOI: 10.1371/journal.pone.0089957.

17. Yang Y.C., Zhang N., Van Crombruggen K. et al. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 2012; 67 (10): 1193–1202. DOI: 10.1111/j.1398-9995.2012.02880.x.

18. Shah R., Hurley C.K., Posch P.E. A molecular mechanism for the differential regulation of TGF-beta1 expression due to the common SNP -509C-T (c. -1347C > T). Hum. Genet. 2006; 120 (4): 461–469. DOI: 10.1007/s00439-006-0194-1.

19. Jakimiuk A., Nowicka M., Bogusiewicz M. et al. Prevalence of estrogen receptor alpha PvuII and XbaI polymorphism in population of Polish postmenopausal women. Folia. Histochem. Cytobiol. 2007; 45 (4): 331–338.

20. Koppelman G.H., Sayers I. Evidence of a genetic contribution to lung function decline in asthma. J. Allergy Clin. Immunol. 2011; 128 (3): 479–484. DOI: 10.1016/j.jaci.2011.05.036.

21. Uhal B.D., Kim J.K., Li X., Molina-Molina M. Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr. Pharm. Des. 2007; 13 (12): 1247–1256.

22. Daing A., Singh S.V., Saimbi C.S. et al. Single nucleotide polymorphisms at interleukin (IL)-1 b + 3954 and vitamin D receptor (VDR) TaqI in chronic periodontitis patients: A pilot study in North Indian population. J. Int. Clin. Dent. Res. Organ. 2015; 7: 18–23. DOI: 10.4103/2231-0754.153490.

23. Perna L., Butterbach K., Haug U. et al. Vitamin D receptor genotype rs731236 (Taq1) and breast cancer prognosis. Cancer Epidemiol. Biomarkers Prev. 2013; 22 (3): 437–442. DOI: 10.1158/1055-9965.EPI-12-0970-T.

24. Barna B.P., Culver D.A., Kanchwala A. et al. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J. Innate Immun. 2012; 4 (5–6): 569–578. DOI: 10.1159/000339149.

25. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol. Cell Endocrinol. 2010; 321 (2): 103–111. DOI: 10.1016/j.mce.2010.02.013.

26. Rivera N.V., Ronninger M., Shchetynsky K. et al. High-density genetic mapping identifies new susceptibility variants in sarcoidosis phenotypes and shows genomic-driven phenotypic differences. Am. J. Respir. Crit. Care Med. 2016; 193 (9): 1008–1022. DOI: 10.1164/rccm.201507-1372OC.